人表皮生长因子受体2低表达乳腺癌临床诊疗共识(2022版)

Consensus on clinical diagnosis and treatment of breast cancer with low expression of human epidermal growth factor receptor 2(2022 edition)

近年来,人表皮生长因子受体2(HER-2)低表达乳腺癌的治疗成为乳腺癌诊疗的热点问题。随着抗体药物偶联物在HER-2低表达乳腺癌患者疗效的确立,HER-2低表达或成为乳腺癌新的靶向治疗亚型。规范诊疗是保证相关疗效的前提,为了更好地规范HER-2低表达乳腺癌临床合理诊疗,中国抗癌协会国际医疗与交流分会和中国医师协会肿瘤医师分会乳腺癌学组参考国内外最新临床研究以及近年来发表的重要参考文献,结合中国病理科医师和肿瘤科医师的临床经验,经专家组讨论后形成HER-2低表达乳腺癌临床诊疗共识,以期加深临床肿瘤医师对HER-2低表达乳腺癌的认识,推进临床决策的精准化,达到延长患者生存时间和提高生活质量的最终目标。

The treatment of breast cancer with low expression of human epidermal growth factor receptor 2(HER-2)has become a focused area in recent years.With the proved therapeutic effect of antibody-drug conjugate on breast cancer patients with HER-2 low expression,HER-2-low expression may become a new subtype for targeted therapies of breast cancer.Standardized diagnosis and treatment are the foundation to guarantee efficacy.In order to improve the standardization of clinical diagnosis and treatment of HER-2-low breast cancer,the Consensus Expert Committee has summarized the latest domestic and global clinical data and the key relevant publications in recent years.We have combined them with clinical experience of pathologists and oncologists,had a deep discussion within the committee,and developed the consensus.We believe this consensus could help clinicians improve the understanding about HER-2-low breast cancer,promote the accuracy of decision-making and achieve the ultimate goal of prolonging the overall survival and improving the quality of life of patients.